Joseph Nabhan

Joseph Nabhan

Company: Vesigen Therapeutics

Job title: Chief Scientific Officer


Prior to joining Vesigen, Joe held scientific and leadership positions in several pharmaceutical companies. Most recently, he headed an RNA biology group at Astellas Innovation Management in Cambridge, where he initiated numerous early drug discovery programs and external collaborations using multiple modalities. Previously, Joe held roles of increasing responsibility in the Rare Disease Research Unit of Pfizer, where he led several programs from early discovery through lead development and a number of external collaborations with biotech and academic labs.

While a postdoctoral fellow in Quan Lu’s lab at the Harvard T.H. Chan School of Public Health, Joe led the study that discovered a new class of microvesicles called ARMMs (ARRDC1 mediated microvesicles). He received his Ph.D. from McGill University.


Engineering ARRDC1-Mediated Microvesicles (ARMMs) for Targeted Non-Viral Delivery of Large Payloads 3:15 pm

ARMMs are modular vehicles for delivery of Cas/gRNA RNPs, RNA, and effector proteins ARMMs have a differentiated biodistribution to a range of tissue and cell types ARMMs can be surface engineered with targeting moieties to direct tropism to specific cell typesRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.